Aug. 5 at 4:58 AM
$ARDX For investors, the strong revenue growth and beat on expectations are positive, but the continued net loss and increasing expenses warrant caution. The company's cash position provides a buffer, but profitability remains a future goal rather than a current reality. For patients and healthcare providers, the strong performance of IBSRELA and XPHOZAH underscores their clinical and commercial value, potentially expanding access to these treatments.
The revenue growth in Q2 2025 was primarily driven by IBSRELA, which generated
$65.0 million in net sales, an 84% increase year-over-year. This growth reflects strong market demand and effective commercialization strategies, The company also raised its 2025 full-year IBSRELA net sales guidance to
$250-
$260 million, up from the previous
$240-
$250 million.
Long-term, Ardelyx anticipates IBSRELA to achieve peak annual net sales exceeding
$1 billion
